This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ma, L. Articles by Pandolfi, P. P. Search for Related Content PubMed PubMed Citation Articles by Ma, L. Articles by Pandolfi, P. P.

Identification of S664 TSC2 Phosphorylation as a Marker for Extracellular Signal-Regulated Kinase–Mediated mTOR Activation in Tuberous Sclerosis and Human Cancer

¹ Cancer Biology and Genetics Program and ² Department of Pathology, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center; ³ Graduate Program in Physiology, Biophysics and Systems Biology, Weill Graduate School of Medical Sciences, Cornell University, New York, New York; and Departments of ⁴ Pediatrics, ⁵ Neurology, and ⁶ Pathology, University of Cincinnati College of Medicine, Cincinnati, Ohio

Requests for reprints: Pier Paolo Pandolfi, Cancer Biology and Genetics Program, Department of Pathology, Memorial Sloan-Kettering Cancer Center, Box 110, 1275 York Avenue, New York, NY 10021. Phone: 212-639-6168; Fax: 212-717-3102; E-mail: p-pandolfi{at}ski.mskcc.org.

Constitutive activation of extracellular signal-regulated kinases (Erk1/2) is frequently implicated in human cancers. Recently, aberrantly activated Erk was also found in brain lesions associated with tuberous sclerosis (TSC). We reported previously that Erk might contribute to tumorigenesis by phosphorylating TSC2 at specific residues, particularly S664. In our present study, 25 TSC-related cortical tubers or subependymal giant cell astrocytomas, as well as tissue microarrays of six types of human cancers, were analyzed for the expression of phospho-Erk (pErk) 1/2, S664-phospho-TSC2 (pTSC2), and phospho-S6 (pS6) by immunohistochemistry. We found that Erk-mediated TSC2 phosphorylation occurred at a high incidence and positively correlated with mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR) activation in TSC-associated brain lesions as well as in various cancers. Interestingly, in certain types of cancers (e.g., breast carcinoma and colon carcinoma), S664-pTSC2 seemed to be a more sensitive marker than pErk. Furthermore, most of the pTSC2-positive samples (75%) were positive for pS6, but only 40% to 55% of the pS6-positive tumors exhibited TSC2 phosphorylation. Our results show that S664 TSC2 phosphorylation is a marker for Erk-mediated (as opposed to Akt-mediated) mTOR activation in TSC and human cancer. On the basis of these findings, TSC2 phosphorylation at S664 can be used to identify patients that may benefit from antitumor therapy with MAPK and mTOR inhibitors. Importantly, our results indicate that Erk-mediated phosphorylation and inactivation of TSC2 can be critical in development of hamartomatous lesions in TSC and cancer pathogenesis. [Cancer Res 2007;67(15):7106–12]

This article has been cited by other articles:

				E. Klann Thwarting Dyskinesia by Targeting mTORC1 Sci. Signal., July 21, 2009; 2(80): pe42 - pe42. [Abstract] [Full Text] [PDF]

				R. G. Maki, D. R. D'Adamo, M. L. Keohan, M. Saulle, S. M. Schuetze, S. D. Undevia, M. B. Livingston, M. M. Cooney, M. L. Hensley, M. M. Mita, et al. Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas J. Clin. Oncol., July 1, 2009; 27(19): 3133 - 3140. [Abstract] [Full Text] [PDF]

				G. Distefano, M. Boca, I. Rowe, C. Wodarczyk, L. Ma, K. B. Piontek, G. G. Germino, P. P. Pandolfi, and A. Boletta Polycystin-1 Regulates Extracellular Signal-Regulated Kinase-Dependent Phosphorylation of Tuberin To Control Cell Size through mTOR and Its Downstream Effectors S6K and 4EBP1 Mol. Cell. Biol., May 1, 2009; 29(9): 2359 - 2371. [Abstract] [Full Text] [PDF]

				A. S. Rocha, S. Paternot, K. Coulonval, J. E. Dumont, P. Soares, and P. P. Roger Cyclic AMP Inhibits the Proliferation of Thyroid Carcinoma Cell Lines through Regulation of CDK4 Phosphorylation Mol. Biol. Cell, November 1, 2008; 19(11): 4814 - 4825. [Abstract] [Full Text] [PDF]

				W. Feng, R. E. Brown, C. D. Trung, W. Li, L. Wang, T. Khoury, S. Alrawi, J. Yao, K. Xia, and D. Tan Morphoproteomic Profile of mTOR, Ras/Raf Kinase/ERK, and NF-{kappa}B Pathways in Human Gastric Adenocarcinoma Ann. Clin. Lab. Sci., January 1, 2008; 38(3): 195 - 209. [Abstract] [Full Text] [PDF]